^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:everolimus (mTOR inhibitor) +
    exemestane (Aromatase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Sci Rep
    Title:

    Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer

    Published date:
    03/10/2021
    Excerpt:
    In contrast, PIK3CA mutations were significantly associated with longer TTP in patients receiving EverX treatment (median TTP of EverX: 15.9 months vs. 5.2 months, p = 0.01) and remained a significant factor in multivariable analysis for TTP of EverX in this subgroup (hazard ratio = 0.2, 95% CI = 0.1- 0.8, p = 0.03).
    DOI:
    10.1038/s41598-021-84999-9